從“雙引擎”到“第三極”，不變的是內生定力 | Bilingual

編者按：在耐心的土壤里，見證產業浪潮奔涌；在時間的長河里，以非凡的定力擁抱變化。

眾所周知，在藥明康德一體化CRDMO平臺上，龐大的體量之中，蘊藏著很多內生的增長力量。不僅“小分子化學+TIDES（寡核苷酸/多肽）”雙引擎一直動力強勁，在最新的藥明康德一季度業績中，更豐富的內生增長曲線正在加速顯現，這“第三增長極”就是“生物學+測試”一體化研發服務。

2026年一季度，藥明康德處于研發最前端生物學業務（涵蓋靶點驗證、體外藥效、作用機制研究等），以及測試業務（涵蓋藥代動力學、毒理學、生物分析等實驗室測試），雙雙再創新高。生物學業務板塊實現了10.1%的雙位數增長，單季度營收達到6.7億元；測試業務實現了27.4%的增長，單季度營收達到11.3億元。

為何生物學業務和測試業務能夠有如此明顯的增長？又反映了行業怎樣的發展態勢？藥明康德高級副總裁，測試業務平臺、生物學業務平臺、自動化部負責人彭宣嘉博士分享了他的理解與思考。

窗外，是藥明康德國際化標準的新藥研發服務園區，映著春日上海的勃勃生機；窗內，一場關于科技驅動和生物醫藥產業未來的探討，正以超出預期的深度和廣度展開。

科技驅動，早期藥物發現效率提升

全球新藥研發的范式，總是在發生一次次深刻的改變，但變革與進化在醫藥健康產業再正常不過。彭宣嘉指出，核心驅動力是科技發展持續推動著行業創新壁壘的降低。

“過去，發現一個先導化合物，可能需要合成、篩選成千上萬個分子，過程如同大海撈針。新型篩選技術層出不窮，將大大提高藥物發現的初始效率。”他舉了一個例子，“比如DNA編碼化合物庫（DEL）技術。在一個小小的EP管里，一次實驗就能對百億級的化合物進行篩選，將原先數月的篩選工作壓縮到數周。”

然而，他話鋒一轉，強調這并不意味著傳統的高通量篩選（HTS）會被取代。“行業里常有一種誤區，認為新范式會徹底顛覆舊模式。但現實往往是疊加與融合。DEL技術擅長海量初篩，而HTS在后續的確證與優化中依然不可替代。關鍵是，我們能否根據客戶項目的特點，提供最適配的技術解決方案。”

如今，虛擬篩選技術的出現，使得新藥發現的場景從實驗室切換到計算機。但無論是多么完美的虛擬分子，最終都必須走出比特世界，進入現實世界合成出來——它的活性、毒性、代謝性質、成藥性，必須經過分子水平、細胞水平、動物模型，乃至臨床試驗的層層嚴苛檢驗。

虛擬世界極大提升了探索的廣度和設計的成功率，催生了更多需要被驗證的、被寄予厚望的候選分子。這直接導致對下游實體驗證服務的需求“通量”呈指數級提升。

隨著產業有望步入AI科技賦能的“超高效”創新時代，“第三增長極”理應擁有更大的想象空間。

“當源頭創新的通量不斷加大，未來會是可以預見的‘春江水暖’。”彭宣嘉博士透露。

新分子崛起，推動產業不斷突破

談起過去二十余年的行業變遷，他表示，“新藥研發，是一個需要極度耐心的行業。一款新藥從靶點到患者，動輒十年，數十億美金的投入，其間充滿未知與挑戰，但這更是一個生命力極其蓬勃的行業。每當某個疾病領域或技術路徑快要觸及天花板時，總會有新的科學奇點爆發，重新點燃整個生態的熱情，推動產業向前。”

彭宣嘉的職業生涯，伴著藥明康德見證了近年來醫藥研發服務產業的崛起。他親歷了從小分子化學藥獨霸天下，到抗體藥物嶄露頭角，再到如今新分子實體（NMEs）百花齊放的迭代周期。尤其是近年來，多肽、寡核苷酸、PROTAC、GLP-1等，如同一個個接續爆發的能量奇點，不斷突破傳統認知的壁壘，重塑全球研發的格局與想象力。

在藥明康德最新公布的2026年一季度業績中，新分子貢獻了生物學業務（WuXi Biology）及測試業務（WuXi Testing）超過30%的營收，這一數字讓新分子浪潮的力度具象化了。

對此，彭宣嘉博士這樣理解，“這背后是全球成千上萬的科學家和企業，對未被滿足的治療需求發起的持續攻堅。無論外部環境如何波瀾起伏，創新力量始終在引導行業向上。而我們藥明康德要做的，就是深刻理解合作伙伴的研發創新需求，并擁抱這個因創新而不斷變化的世界。”

這正是彭宣嘉眼中，CXO價值在新時代的升華。當各類新分子、新科技層出不窮，行業非但不會“去CXO化”，反而在催生更復雜、更高難度的研發需求, “蛋糕”只會變得更大。

高難需求，催生行業加速分化

在監管日益嚴格、藥企對研發質量與成功率追求極致的當下，CXO行業將會加速分化，訂單呈現出明顯的“馬太效應”，快速向此類具備完整能力、國際最高合規標準、能夠提供確定性結果的頭部平臺集中。

“這不是偶然，”彭宣嘉博士指向背后的產業邏輯，“分子發現正在變得更加高效，但生物學的復雜性并未因此減少。對分子作用機制的深入理解、對安全性的全面評估，變得比以往任何時候都更加重要和緊迫。”

當創意的門檻降低，將創意轉化為現實的門檻反而在提高。誰能夠幫助虛擬世界的分子高效轉化為現實，在當下的產業環境中顯得更加稀缺和重要。

而這恰恰是藥明康德的長板，畢竟藥明康德是“一體化、端到端”的CRDMO模式，覆蓋研究（R）、開發（D）和生產（M）全鏈路，其核心優勢在于“一體化”帶來的無縫銜接。

生物學業務常年作為 “流量入口”，持續為藥明康德帶來20%的新增客戶。一個在生物學平臺被驗證有效的分子，可以高效地進入測試平臺進行安全評價，其產生的所有數據又為后續的商業化開發鋪平道路。

“我們看到的不僅是單個業務線的增長，更是‘生物學-測試’與化學業務間產生的強大協同效應，為后期持續帶來機遇。”彭宣嘉博士補充道。

對于尋求更大確定性的跨國藥企和Biotech而言，藥明康德無論從能力縱深還是未來延展性上都是一個非常好的選擇。

時間的復利，鑄就最深的護城河

在技術日新月異、風口輪流變換的醫藥行業，藥明康德何以能一次次精準地承接產業浪潮，并轉化為持續增長的動力？彭宣嘉博士將答案歸于四個字：時間復利。

“客戶今日的信任，絕非一蹴而就。那是公司25年來，沿著‘做對的事、把事做好’這條看似樸素、實則極具韌性的道路，一步步積累出的厚重資產。”

這復利的本質，是深度理解與靈活響應。25年的歷程，讓藥明康德穿越了多個行業周期，服務了從全球頂尖跨國制藥巨頭到初創生物科技公司的幾乎全譜系客戶。“我們深刻理解，跨國藥企的需求與Biotech的需求，在底層邏輯上相通，但在具體形態上迥異。”彭宣嘉博士分析道。

跨國藥企追求的是規模化、系統化的卓越與絕對的確定性，管線龐大，項目流程復雜，更看重合規質量、全球同步、穩定交付。藥明康德用25年搭建的、橫跨全球監管機構的完整基礎設施網絡，以及與之匹配的、經過千萬次驗證的國際質量體系，能充分滿足這種高標準的需求。

Biotech公司，特別是那些由頂尖科學家創立、懷抱突破性技術的初創企業，需要合作伙伴更加全方位的賦能，成為其核心團隊的能力延伸，在充滿不確定性的研發道路上快速推進項目進程，更看重敏捷和高效。藥明康德一體化平臺的價值在此凸顯，以全鏈條資源，以“模塊化、可擴展”的服務，支撐從“一張紙”的創意走向臨床概念的驗證，并推進至后期乃至商業化。“我們像是他們的外部研發部門，能快速響應，陪伴他們度過最充滿挑戰也最決定命運的研發階段。”彭宣嘉博士說。

這種同時服務“高標準”與“高靈敏”的能力，并非簡單的業務疊加，而是源于二十余載深耕中錘煉出的體系彈性與組織智慧。平臺既擁有滿足FDA、EMA等國際標準的剛性質量框架，又培育了追求極致的服務理念，才能成為不同背景、不同階段創新者堅定的選擇。

“信任的建立，始于一次成功的交付，但鞏固于無數次關鍵時刻的‘值得托付’。”彭宣嘉博士指出。這份用時間、專業與無數成功案例積累的信任資產，構成了藥明康德應對一切技術變遷與市場起伏時，最深沉、最穩固的能力底盤。

變化的時代與最好的未來

訪談臨近尾聲，窗外的陽光正盛。彭宣嘉博士的從理性的剖析，自然而然地轉向了更遼闊的展望。

“這個世界唯一不變的，就是變化本身，但作為賦能者，我們也要努力在變化中保持內核的穩定。”彭宣嘉站在窗前，園區內研發樓宇鱗次櫛比，承載著來自全球客戶無數未竟的探索。“我們要做的，就是以二十五年來錘煉的確定性的‘不變’——對質量的執著、對科學的敬畏、對客戶的承諾——去擁抱這個世界的無限可能。”

變化的時代，屬于那些敢于創新的探索者，也屬于那些默默夯實基礎、為創新保駕護航的賦能者。他堅信，藥明康德所選擇的賦能者之路，在新時代里將越走越寬。

“讓天下沒有難做的藥，難治的病” —— 這不僅是藥明康德懸掛在墻上的愿景，更是貫穿其二十多年發展歷程的精神內核。

如今，隨著科技日新月異，這幅藍圖，正從理想照進現實。

“我們正無限接近這個夢想。”彭宣嘉博士最后說道。

How WuXi AppTec’s Integrated Biology and Testing Services Help Accelerate Drug R&D

The closer discovery, testing, development, and manufacturing are linked, the faster scientific ideas can be translated into medicines for patients. For over 25 years, WuXi AppTec’s end-to-end integrated CRDMO model has been not only a defining feature of the company’s strategy, but also a foundation for durable growth.

The company’s 2026 Q1 results offer a snapshot of how that model continues to evolve. WuXi Biology and WuXi Testing both delivered steady growth, reflecting rising demand for the scientific capabilities that bridge early discovery and downstream development.

To better understand what is driving that momentum, Dr. Xuanjia Peng, Senior Vice President of WuXi AppTec and head of WuXi Testing and WuXi Biology, shared his perspective on how technical complexity and broader industry shifts are redefining drug research, and how WuXi AppTec's integrated biology and testing platforms are evolving to help accelerate R&D.

Technology Is Redefining Early Drug Discovery

Drug discovery has always evolved alongside advances in science and technology, but today, the pace of change is accelerating. According to Dr. Peng, one fundamental dynamic remains constant: technological innovation continues to lower barriers to drug discovery.

New technologies are drastically reducing the barriers to early discovery, enabling scientists to identify promising compounds with greater speed and scale. Dr. Xuanjia Peng points to DNA-Encoded Library (DEL) technology as one example: what once required synthesizing and screening thousands of molecules can now involve billions of compounds screened in a single experiment, compressing months of work into weeks.

“Scientific progress is often cumulative,” Dr. Peng said. “The question is not whether one technology replaces another, but whether you can apply the right technology to the right problem.”

DEL has transformed large-scale primary screening, while traditional high-throughput screening remains essential for downstream confirmation and optimization. Virtual screening has pushed more discovery into the computational realm—but digital promise still demands real-world validation. Molecules must be synthesized, tested and rigorously evaluated for biological activity, safety, metabolism, and developability before they can move forward.

That is shifting value downstream. As front-end discovery becomes more productive, demand is rising for the scientific capabilities that validate, de-risk, and translate promising molecules into viable development candidates. Against this backdrop, WuXi AppTec’s continued growth in biology and testing suggests a meaningful runway ahead.

New Modalities, New Demands

Drug research, in Dr. Xuanjia Peng’s view, remains one of the most demanding and constantly evolving areas in science. Bringing a medicine from discovery to market can take more than a decade and require billions in investment, he noted, in a process defined by uncertainty and complexity, but also continuous technological renewal.

As one therapeutic frontier matures, new modalities tend to emerge, resetting the boundaries of what is possible. That shift has accelerated in recent years, from peptides and oligonucleotides to PROTACs, each reshaping global R&D priorities.

The impact is already visible at WuXi AppTec. In first-quarter 2026 results, new modality-related work accounted for more than 30% of revenue across WuXi Biology and WuXi Testing.

For Dr. Peng, the figure reflects broader industry momentum. “Innovation remains the central force driving this field,” he said. “Our role is to deeply understand our partners’ scientific and development needs—and continue evolving alongside a world being constantly reshaped by innovation.”

Higher Technical Complexity Is Accelerating Industry Differentiation

For Dr. Peng, one paradox defines modern drug R&D: discovery is becoming more efficient, while development is becoming more demanding.

“Biology remains extraordinarily complex,” he said. “A deeper understanding of mechanism, translational relevance, and safety is becoming more important—not less.”

That dynamic is accelerating differentiation across the CRO and CDMO sector. As regulatory expectations rise and scientific questions grow more complex, biopharma companies are increasingly gravitating toward partners that combine technical breadth, operational rigor, and reliable execution.

In that environment, integrated platforms matter more than ever.

WuXi AppTec’s end-to-end CRDMO model is designed to connect research, development, and manufacturing into a continuous value chain—reducing friction between stages and improving development certainty. Biology often serves as an early gateway, with validated molecules advancing efficiently into preclinical testing and beyond.

“What matters is not individual capabilities in isolation,” Dr. Peng said. “It is how biology, testing, and chemistry work together—and the long-term value that creates.”

Trust, Built Over Time

If integration creates operational advantage, trust creates durability.

Dr. Peng attributes WuXi AppTec’s long-term competitive position not to any single capability, but to decades of accumulated execution—what he describes simply as “doing the right thing, and doing it right.”

That discipline has allowed the company to build relationships across the full spectrum of innovators, from global pharmaceutical companies seeking scale, compliance, and execution certainty, to emerging biotech firms that prioritize speed, flexibility, and scientific partnership.

Their needs may differ. Their goal does not: turning promising science into medicines. For larger companies, WuXi AppTec offers global infrastructure, internationally aligned quality systems, and dependable delivery at scale. For biotech innovators, it can act more like an extension of the R&D team—providing modular, end-to-end support from concept to clinical proof.

The platform combines a robust quality framework designed to meet the high standards of global regulators—including the U.S. Food and Drug Administration and the European Medicines Agency—with a deeply embedded service culture focused on scientific excellence and customer success. Together, these elements have made WuXi AppTec a trusted partner for innovators across geographies, business models, and stages of growth.

“In critical moments, customers need to know they can rely on you,” Dr. Peng said. “That trust is built over time—and reinforced through delivery.”

Staying Constant in a Changing Industry

“The only true constant is change,” Dr. Peng said. “For those enabling innovation, the challenge is to remain steady at the core while continuously adapting to what is changing around us.”

What matters, Dr. Peng argues, is maintaining clarity about what should not change: scientific rigor, uncompromising quality, and a deep commitment to customers.

In healthcare innovation, breakthroughs may capture headlines. But bringing those breakthroughs to patients depends just as much on the less visible work of validation, development, and execution—the systems that translate scientific possibility into medical reality. That is where WuXi AppTec sees its role: not simply following innovation, but helping make it possible.

“Every drug can be made, and every disease can be treated,” he said. “It is the vision that has guided our development over the past 25 years.” And as science advances at unprecedented speed, that vision is increasingly within reach. “We are getting closer to that goal every day,” Dr. Peng said.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。